Molecular/JJ
Characterization/NN
of/IN
Legionellosis/NN
Drug/NN
Target/NN
Candidate/NN
Enzyme/NN
Phosphoglucosamine/NN
Mutase/NN
from/IN
Legionella/NN
pneumophila/NN
(/(
strain/NN
Paris/NN
)/)
:/:
An/DT
In/IN
Silico/NN
Approach/NN
./.
====================
The/DT
harshness/VBP
of/IN
legionellosis/NN
differs/VBZ
from/IN
mild/JJ
Pontiac/NN
fever/NN
to/TO
potentially/RB
fatal/JJ
Legionnaire/NN
's/POS
disease/NN
./.
====================
The/DT
increasing/VBG
development/NN
of/IN
drug/NN
resistance/NN
against/IN
legionellosis/NN
has/VBZ
led/VBD
to/TO
explore/VB
new/JJ
novel/JJ
drug/NN
targets/NNS
./.
====================
It/PRP
has/VBZ
been/VBN
found/VBN
that/IN
phosphoglucosamine/NN
mutase/NN
,/,
phosphomannomutase/NN
,/,
and/CC
phosphoglyceromutase/NN
enzymes/NNS
can/MD
be/VB
used/VBN
as/IN
the/DT
most/JJS
probable/JJ
therapeutic/JJ
drug/NN
targets/NNS
through/IN
extensive/JJ
data/NNS
mining/VBG
./.
====================
Phosphoglucosamine/NN
mutase/NN
is/VBZ
involved/VBN
in/IN
amino/NN
sugar/VBP
and/CC
nucleotide/NN
sugar/VBP
metabolism/NN
./.
====================
The/DT
purpose/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
predict/VB
the/DT
potential/JJ
target/NN
of/IN
that/DT
specific/JJ
drug/NN
./.
====================
For/IN
this/DT
,/,
the/DT
3D/NN
structure/NN
of/IN
phosphoglucosamine/NN
mutase/NN
of/IN
Legionella/NN
pneumophila/NN
(/(
strain/NN
Paris/NN
)/)
was/VBD
determined/VBN
by/IN
means/NNS
of/IN
homology/NN
modeling/VBG
through/IN
Phyre2/NN
and/CC
refined/VBD
by/IN
ModRefiner/NN
./.
====================
Then/RB
,/,
the/DT
designed/VBN
model/NN
was/VBD
evaluated/VBN
with/IN
a/DT
structure/NN
validation/NN
program/NN
,/,
for/IN
instance/NN
,/,
PROCHECK/NN
,/,
ERRAT/NN
,/,
Verify3D/NNP
,/,
and/CC
QMEAN/NN
,/,
for/IN
further/JJ
structural/JJ
analysis/NN
./.
====================
Secondary/JJ
structural/JJ
features/NNS
were/VBD
determined/VBN
through/IN
self-optimized/VBN
prediction/NN
method/NN
with/IN
alignment/NN
(/(
SOPMA/NN
)/)
and/CC
interacting/VBG
networks/NNS
by/IN
STRING/NN
./.
====================
Consequently/RB
,/,
we/PRP
performed/VBD
molecular/JJ
docking/NN
studies/NNS
./.
====================
The/DT
analytical/JJ
result/NN
of/IN
PROCHECK/NN
showed/VBD
that/IN
95.0/CD
%/NN
of/IN
the/DT
residues/NNS
are/VBP
in/IN
the/DT
most/JJS
favored/VBD
region/NN
,/,
4.50/CD
%/NN
are/VBP
in/IN
the/DT
additional/JJ
allowed/VBD
region/NN
and/CC
0.50/CD
%/NN
are/VBP
in/IN
the/DT
generously/RB
allowed/VBD
region/NN
of/IN
the/DT
Ramachandran/NN
plot/NN
./.
====================
Verify3D/RB
graph/NN
value/NN
indicates/VBZ
a/DT
score/NN
of/IN
0.71/CD
and/CC
89.791/CD
,/,
1.11/CD
for/IN
ERRAT/NN
and/CC
QMEAN/NN
respectively/RB
./.
====================
Arg419/NN
,/,
Thr414/NN
,/,
Ser412/NN
,/,
and/CC
Thr9/NN
were/VBD
found/VBN
to/TO
dock/VB
the/DT
substrate/NN
for/IN
the/DT
most/JJS
favorable/JJ
binding/NN
of/IN
S-mercaptocysteine/NN
./.
====================
However/RB
,/,
these/DT
findings/NNS
from/IN
this/DT
current/JJ
study/NN
will/MD
pave/VB
the/DT
way/NN
for/IN
further/JJ
extensive/JJ
investigation/NN
of/IN
this/DT
enzyme/NN
in/IN
wet/JJ
lab/NN
experiments/NNS
and/CC
in/IN
that/DT
way/NN
assist/VBP
drug/NN
design/NN
against/IN
legionellosis/NN
./.
====================
Legionella/NN
pneumophila/NN
is/VBZ
a/DT
gram-negative/JJ
intracellular/JJ
facultative/JJ
pathogen/NN
that/DT
is/VBZ
mainly/RB
responsible/JJ
behind/VBP
hospital/JJ
and/CC
community-acquired/VBD
legionellosis/NN
and/CC
about/RB
90/CD
%/NN
cases/NNS
of/IN
legionellosis/NN
are/VBP
caused/VBN
by/IN
this/DT
species/NNS
[/(
1/CD
]/)
./.
====================
Legionellosis/NN
patients/NNS
predominantly/RB
have/VBP
pneumonia/NN
,/,
chills/NNS
,/,
fever/NN
even/RB
their/PRP$
cough/IN
likely/JJ
to/TO
be/VB
dry/JJ
or/CC
phlegm/NN
nature/NN
./.
====================
L./FW
pneumophila/FW
isolation/NN
by/IN
comparing/VBG
clinical/JJ
and/CC
environmental/JJ
L./FW
pneumophila/FW
isolates/NNS
precludes/VBZ
different/JJ
sources/NNS
whether/IN
it/PRP
is/VBZ
contagious/JJ
or/CC
not/RB
through/IN
a/DT
number/NN
of/IN
typing/NN
methods/NNS
./.
====================
Such/JJ
methods/NNS
of/IN
typing/JJ
make/VBP
it/PRP
's/POS
easier/RBR
like/IN
pulsed-field/JJ
gel/NN
electrophoresis/NN
(/(
PFGE/NN
)/)
,/,
is/VBZ
usually/RB
considered/VBN
to/TO
be/VB
extremely/RB
biased/VBN
[/(
2/CD
,/,
3/CD
,/,
4/CD
,/,
5/CD
,/,
6/CD
]/)
./.
====================
PFGE/NN
can/MD
recognize/VB
unique/JJ
strains/NNS
of/IN
L./FW
pneumophila/FW
with/IN
a/DT
precise/JJ
profile/NN
that/DT
is/VBZ
considered/VBN
sporadic/JJ
./.
====================
The/DT
origin/NN
of/IN
L./FW
pneumophila/FW
sg/NN
1/CD
clone/NN
was/VBD
identified/VBN
at/IN
1997/CD
./.
====================
In/IN
Paris/NN
,/,
legionellosis/NN
was/VBD
caused/VBN
by/IN
a/DT
single/JJ
L./FW
pneumophila/FW
sero/NN
group/NN
1/CD
strain/NN
[/(
7/CD
]/)
./.
====================
An/DT
ample/JJ
of/IN
enzymes/NNS
is/VBZ
required/VBN
in/IN
bacterial/JJ
metabolism/NN
./.
====================
Drugs/NNS
resistance/NN
against/IN
L./FW
pneumophila/FW
considered/VBN
to/TO
the/DT
search/NN
for/IN
most/JJS
novel/JJ
drugs/NNS
of/IN
designing/VBG
./.
====================
At/IN
present/JJ
,/,
computational/JJ
analysis/NN
was/VBD
taken/VBN
place/NN
in/IN
order/NN
to/TO
discover/JJ
novel/JJ
drug/NN
targets/NNS
that/WDT
are/VBP
non-homologous/JJ
to/TO
human/JJ
./.
====================
All/DT
enzymes/NNS
involved/VBN
in/IN
metabolic/JJ
pathway/NN
of/IN
those/DT
certain/JJ
bacteria/NNS
are/VBP
precursor/NN
to/TO
design/VB
such/JJ
kind/NN
of/IN
drugs/NNS
./.
====================
Phosphoglucosaminemutase/NN
and/CC
phosphomannomutase/NN
,/,
these/DT
two/CD
typically/RB
have/VBP
the/DT
potential/JJ
target/NN
sites/NNS
./.
====================
Phosphomannomutase/NN
is/VBZ
processed/VBN
with/IN
glycosylation/NN
,/,
adding/VBG
the/DT
groups/NNS
of/IN
sugar/JJ
molecules/NNS
(/(
oligosaccharides/NNS
)/)
to/TO
proteins/NNS
./.
====================
The/DT
enzyme/NN
phosphoglucosamine/NN
mutase/NN
catalyzes/VBZ
the/DT
chemical/JJ
reaction/NN
alpha-D-glucosamine/NN
1-phosphate/JJ
to/TO
D-glucosamine/JJ
6-phosphate/JJ
,/,
which/WDT
converts/VBZ
alpha-D-glucosamine/NN
1-phosphate/JJ
to/TO
D-glucosamine/JJ
6-phosphate/JJ
./.
====================
This/DT
enzyme/NN
is/VBZ
phenomenally/RB
the/DT
same/JJ
as/IN
phosphomannomutase/NN
,/,
which/WDT
transfers/VBZ
a/DT
phosphate/NN
group/NN
within/IN
a/DT
molecule/NN
./.
====================
The/DT
systematic/JJ
name/NN
of/IN
phosphoglucosamine/NN
mutase/NN
is/VBZ
alpha-D-glucosamine/NN
1,6-phosphomutase/NN
./.
====================
It/PRP
participates/VBZ
in/IN
metabolism/NN
of/IN
amino/NN
sugars/VBZ
./.
====================
Phosphoglucosamine/NN
mutase/NN
(/(
GlmM/NN
)/)
catalyzes/VBZ
the/DT
formation/NN
of/IN
glucosamine-1-phosphate/NN
from/IN
glucosamine-6-phosphate/NN
,/,
an/DT
essential/JJ
step/NN
in/IN
the/DT
pathway/NN
for/IN
UDPN-acetylglucosamine/NN
biosynthesis/NN
in/IN
bacteria/NNS
./.
====================
This/DT
enzyme/NN
must/MD
be/VB
phosphorylated/VBN
to/TO
be/VB
active/JJ
and/CC
acts/VBZ
according/VBG
to/TO
a/DT
ping-pong/JJ
mechanism/NN
involving/VBG
glucosamine-1,6-diphosphate/NN
as/IN
an/DT
intermediate/JJ
[/(
8/CD
]/)
./.
====================
The/DT
phosphoglucosamine/NN
mutase/NN
auto-phosphorylates/VBZ
in/IN
vitro/FW
in/IN
the/DT
presence/NN
of/IN
ATP/NN
./.
====================
The/DT
same/JJ
is/VBZ
pragmatic/JJ
with/IN
phosphoglucosamine/NN
mutases/NNS
from/IN
other/JJ
bacterial/JJ
species/NNS
,/,
yeast/NN
N-acetylglucosamine-phosphate/NN
mutase/NN
,/,
and/CC
rabbit/NN
muscle/NN
phosphoglucomutase/NN
./.
====================
Labeling/VBG
of/IN
GlmM/NN
enzyme/NN
with/IN
ATP/NN
requires/VBZ
divalent/JJ
cation/NN
./.
====================
The/DT
label/JJ
can/MD
be/VB
lost/VBN
if/IN
it/PRP
is/VBZ
incubated/VBN
more/RBR
vigorously/RB
with/IN
of/IN
its/PRP$
substrates/NNS
./.
====================
At/IN
glycosylation/NN
,/,
the/DT
phosphomannomutase/NN
enzyme/NN
converts/NNS
mannose-6-phosphate/VBP
to/TO
mannose-1-phosphate/VB
[/(
9/CD
]/)
./.
====================
Mannose-1-phosphate/JJ
is/VBZ
converted/VBN
into/IN
GDP-mannose/NN
which/WDT
transfers/VBZ
mannose/VBP
to/TO
the/DT
growing/VBG
oligosaccharides/NNS
chain/NN
./.
====================
Congenital/JJ
disorder/NN
type/NN
Iais/NN
is/VBZ
initiated/VBN
by/IN
mutations/NNS
in/IN
the/DT
PMM2/NN
gene/NN
./.
====================
Mutations/NNS
alter/VBP
the/DT
formation/NN
of/IN
phosphomannomutase/NN
enzyme/NN
that/DT
lead/VBP
to/TO
the/DT
reduced/VBN
enzyme/NN
activity/NN
and/CC
shortage/JJ
of/IN
GDP/NN
mannose/VBP
within/IN
cells/NNS
./.
====================
As/IN
there/EX
have/VBP
no/DT
enough/RB
activated/VBN
mannose/VBP
,/,
incorrect/VBP
oligosaccharides/NNS
are/VBP
produced/VBN
./.
====================
Abnormal/JJ
glycosylated/JJ
proteins/NNS
in/IN
organs/NNS
and/CC
tissues/NNS
regulate/VBP
the/DT
signs/NNS
and/CC
symptoms/NNS
in/IN
CDG-Ia/NN
[/(
10/CD
]/)
./.
====================
In/IN
addition/NN
,/,
it/PRP
participates/VBZ
in/IN
the/DT
metabolism/NN
of/IN
both/DT
fructose/JJ
and/CC
mannose/VBP
./.
====================
So/RB
,/,
homology/NN
modeling/VBG
will/MD
predict/VBP
the/DT
desired/VBN
function/NN
and/CC
possible/JJ
disease/NN
treatment/NN
if/IN
needed/VBD
because/IN
of/IN
its/PRP$
importance/NN
on/IN
cell/NN
metabolism/NN
systems/NNS
./.
====================
The/DT
present/JJ
study/NN
is/VBZ
aimed/VBN
to/TO
predict/VB
the/DT
three-dimensional/JJ
(/(
3D/NN
)/)
structure/NN
of/IN
phosphoglucosamine/NN
mutase/NN
by/IN
means/NNS
of/IN
homology/NN
modeling/VBG
./.
====================
Consequently/RB
,/,
to/TO
depict/VB
its/PRP$
structural/JJ
features/NNS
and/CC
to/TO
comprehend/VB
the/DT
molecular/JJ
function/NN
,/,
the/DT
structural/JJ
model/NN
for/IN
the/DT
desired/VBN
protein/NN
was/VBD
constructed/VBN
./.
====================
Sequence/NN
retrieval/NN
====================
The/DT
amino/NN
acid/NN
sequences/NNS
of/IN
the/DT
enzyme/NN
phosphoglucosamine/NN
mutase/NN
in/IN
L./FW
pneumophilia/FW
(/(
strain/NN
Paris/NN
)/)
were/VBD
retrieved/VBN
from/IN
the/DT
UniProt/JJ
Knowledge/NN
Base/NN
(/(
UniProtKB/NN
)/)
database/NN
,/,
which/WDT
is/VBZ
the/DT
foremost/JJ
hub/JJ
for/IN
the/DT
compilation/NN
of/IN
well-designed/JJ
information/NN
on/IN
proteins/NNS
,/,
with/IN
consistent/JJ
,/,
accurate/VBP
,/,
and/CC
rich/JJ
annotation/NN
./.
====================
The/DT
accession/NN
ID/NN
of/IN
phosphoglucosamine/NN
mutase/NN
is/VBZ
Q5X1A3/NN
,/,
and/CC
it/PRP
contains/VBZ
455/CD
amino/NN
acids/NNS
./.
====================
Analysis/NN
of/IN
physico-chemical/JJ
properties/NNS
====================
ProtParam/NN
(/(
http/NN
:/:
//web.expasy.org/protparam//JJ
)/)
,/,
a/DT
tool/NN
of/IN
Expasy/NN
was/VBD
used/VBN
for/IN
the/DT
analysis/NN
of/IN
the/DT
physiological/JJ
and/CC
chemical/JJ
properties/NNS
from/IN
the/DT
protein/NN
sequence/NN
./.
====================
This/DT
tool/NN
can/MD
predict/VB
different/JJ
physico-chemical/JJ
properties/NNS
,/,
like/IN
the/DT
molecular/JJ
weight/NN
,/,
isoelectric/JJ
pH/NN
,/,
aliphatic/JJ
index/NN
,/,
grand/CC
average/NN
of/IN
hydropathicity/NN
(/(
GRAVY/NN
)/)
,/,
and/CC
extinction/NN
coefficients/NNS
./.
====================
Secondary/JJ
structure/NN
prediction/NN
====================
Secondary/JJ
structure/NN
was/VBD
predicted/VBN
by/IN
using/VBG
the/DT
self-optimized/VBN
prediction/NN
method/NN
with/IN
alignment/NN
(/(
SOPMA/NN
)/)
[/(
11/CD
]/)
./.
====================
The/DT
protein/NN
's/POS
secondary/JJ
structure/NN
includes/VBZ
an/DT
α/JJ
helix/NN
,/,
310/CD
helix/NN
,/,
pi/NN
helix/NN
,/,
beta/NN
bridge/NN
,/,
extended/VBD
strand/NN
,/,
beta/NN
turns/NNS
,/,
bend/IN
region/NN
,/,
random/JJ
coil/JJ
,/,
ambiguous/JJ
states/NNS
,/,
and/CC
other/JJ
states/NNS
./.
====================
SOPMA/NN
predicts/VBZ
these/DT
properties/NNS
by/IN
using/VBG
homologous/JJ
protein/NN
identification/NN
,/,
sequence/NN
alignment/NN
,/,
and/CC
conformational/JJ
score/NN
determination/NN
method/NN
./.
====================
Prediction/NN
accuracy/NN
was/VBD
confirmed/VBN
by/IN
correlation/NN
coefficient/JJ
value/NN
./.
====================
Plain/NN
text/NN
format/IN
data/NNS
were/VBD
inputted/VBN
,/,
and/CC
default/NN
parameters/NNS
were/VBD
set/NN
./.
====================
Protein-protein/NN
interaction/NN
networking/VBG
====================
Protein/NN
cooperates/VBZ
with/IN
other/JJ
proteins/NNS
to/TO
perform/VB
accurate/JJ
functions/NNS
./.
====================
To/TO
identify/VB
protein-protein/JJ
interactions/NNS
,/,
STRING/NN
was/VBD
used/VBN
./.
====================
STRING/NN
is/VBZ
a/DT
biological/JJ
database/NN
that/DT
is/VBZ
used/VBN
to/TO
construct/VB
protein-protein/JJ
interaction/NN
(/(
PPI/NN
)/)
networks/NNS
for/IN
different/JJ
known/VBN
and/CC
predicted/VBN
interactions/NNS
./.
====================
At/IN
present/JJ
,/,
the/DT
database/NN
covers/NNS
up/IN
to/TO
5,214,234/CD
proteins/NNS
from/IN
1,133/CD
organisms/NNS
[/(
12/CD
]/)
./.
====================
Model/NN
building/VBG
====================
3D/NN
structure/NN
determination/NN
of/IN
a/DT
protein/NN
is/VBZ
the/DT
key/JJ
step/NN
of/IN
structural/JJ
genomics/NNS
initiative/JJ
[/(
13/CD
]/)
./.
====================
To/TO
predict/VB
the/DT
3D/NN
homology/NN
model/NN
of/IN
phosphoglucosamine/NN
mutase/NN
,/,
Phyre2/NN
(/(
Protein/NN
Homology/Analogy/NN
Recognition/NN
Engine/NN
)/)
[/(
14/CD
]/)
,/,
the/DT
most/JJS
popular/JJ
online/JJ
protein/NN
fold/JJ
identification/NN
server/RB
,/,
was/VBD
used/VBN
./.
====================
Phyre2/NN
uses/VBZ
a/DT
dataset/NN
of/IN
known/VBN
proteins/NNS
taken/VBN
from/IN
different/JJ
reliable/JJ
databases/NNS
,/,
such/JJ
as/IN
Structural/JJ
Classification/NN
of/IN
Proteins/NNS
(/(
SCOP/NN
)/)
database/NN
and/CC
Protein/NN
Data/NNS
Bank/NN
(/(
PDB/NN
)/)
./.
====================
Through/IN
sequential/JJ
steps/NNS
,/,
such/JJ
as/IN
profile/NN
construction/NN
,/,
similarity/NN
analysis/NN
,/,
and/CC
structural/JJ
properties/NNS
,/,
Phyre2/NN
selects/NNS
the/DT
best/JJS
suited/VBN
template/NN
and/CC
generates/VBZ
a/DT
protein/NN
model/NN
./.
====================
To/TO
get/VB
an/DT
accurate/JJ
model/NN
,/,
intensive/JJ
mode/NN
of/IN
protein/NN
modeling/VBG
was/VBD
selected/VBN
./.
====================
The/DT
input/NN
data/NNS
of/IN
this/DT
enzyme/NN
were/VBD
in/IN
FASTA/NN
format/IN
./.
====================
In/IN
this/DT
respect/NN
,/,
the/DT
intensive/JJ
mode/NN
of/IN
protein/NN
modeling/VBG
was/VBD
selected/VBN
in/IN
order/NN
to/TO
get/VB
an/DT
accurate/JJ
model/NN
./.
====================
After/IN
model/NN
building/VBG
,/,
it/PRP
is/VBZ
necessary/JJ
to/TO
further/RBR
refine/NN
in/IN
quest/JJS
of/IN
the/DT
best/JJS
model/NN
generation/NN
./.
====================
Model/NN
refinement/JJ
====================
Homology-based/JJ
modeling/VBG
often/RB
contains/VBZ
significant/JJ
local/JJ
distortions/NNS
that/DT
render/VBP
the/DT
structure/NN
models/NNS
less/RBR
useful/JJ
for/IN
high-resolution/JJ
functional/JJ
analysis/NN
./.
====================
To/TO
refine/VB
the/DT
predicted/VBN
protein/NN
model/NN
,/,
ModRefiner/NNP
[/(
15/CD
]/)
,/,
an/DT
algorithm/NN
for/IN
atomic-level/JJ
,/,
high-resolution/JJ
protein/NN
structure/NN
refinement/JJ
,/,
was/VBD
used/VBN
./.
====================
Protein/NN
sequences/NNS
were/VBD
given/VBN
in/IN
the/DT
FASTA/NN
format/IN
,/,
and/CC
refinement/JJ
was/VBD
done/VBN
for/IN
several/JJ
times/NNS
to/TO
get/VB
the/DT
most/JJS
accurate/JJ
structure/NN
./.
====================
Evaluation/NN
and/CC
validation/NN
of/IN
the/DT
model/NN
====================
The/DT
accuracy/NN
and/CC
stereo/JJ
chemical/JJ
quality/NN
of/IN
the/DT
predicted/VBN
model/NN
were/VBD
evaluated/VBN
with/IN
PROCHECK/NN
[/(
16/CD
,/,
17/CD
]/)
by/IN
Ramachandran/NN
plot/NN
[/(
18/CD
]/)
analysis/NN
,/,
which/WDT
was/VBD
done/VBN
through/IN
``/JJ
Protein/NN
structure/NN
and/CC
model/NN
assessment/NN
tools/NNS
''/NNP
of/IN
Swissmodel/NN
workspace/NN
;/:
2.5/CD
Å/NN
resolution/NN
was/VBD
selected/VBN
for/IN
PROCHECK/NN
analysis/NN
./.
====================
The/DT
best/JJS
model/NN
was/VBD
selected/VBN
on/IN
the/DT
basis/NN
of/IN
overall/JJ
G-factor/NN
,/,
number/NN
of/IN
residues/NNS
in/IN
the/DT
core/NN
,/,
and/CC
allowed/VBD
,/,
generously/RB
allowed/VBD
,/,
and/CC
disallowed/VBD
regions/NNS
./.
====================
ERRAT/NN
[/(
19/CD
]/)
,/,
Verify3D/NNP
[/(
20/CD
]/)
,/,
and/CC
Qualitative/JJ
Model/NN
Energy/NN
Analysis/NN
(/(
QMEAN/NN
)/)
[/(
21/CD
]/)
were/VBD
used/VBN
for/IN
further/JJ
analysis/NN
of/IN
the/DT
selected/VBN
model/NN
./.
====================
The/DT
verified/VBN
structure/NN
was/VBD
visualized/VBN
by/IN
Swiss-PDB/NN
Viewer/JJR
[/(
22/CD
]/)
./.
====================
Active/JJ
site/NN
analysis/NN
====================
The/DT
active/JJ
site/NN
is/VBZ
the/DT
specific/JJ
region/NN
of/IN
the/DT
target/NN
protein/NN
responsible/JJ
for/IN
its/PRP$
activity/NN
and/CC
is/VBZ
constructed/VBN
of/IN
different/JJ
amino/NN
acids/NNS
./.
====================
To/TO
identify/VB
the/DT
active/JJ
site/NN
with/IN
the/DT
determined/VBN
model/NN
,/,
Computed/JJ
Atlas/NNS
of/IN
Surface/NN
Topography/NN
of/IN
proteins/NNS
(/(
CASTp/NN
)/)
[/(
23/CD
]/)
server/RB
was/VBD
used/VBN
./.
====================
This/DT
provides/VBZ
an/DT
online/JJ
resource/NN
for/IN
locating/VBG
,/,
delineating/VBG
,/,
and/CC
measuring/VBG
concave/VBP
surface/NN
regions/NNS
on/IN
three-dimensional/JJ
structures/NNS
of/IN
proteins/NNS
,/,
including/VBG
pockets/NNS
located/JJ
on/IN
protein/NN
surfaces/NNS
and/CC
voids/NNS
buried/VBN
in/IN
the/DT
interior/JJ
of/IN
proteins/NNS
./.
====================
Docking/VBG
simulation/NN
study/NN
====================
Molecular/JJ
docking/NN
is/VBZ
a/DT
computer/NN
simulation/NN
procedure/NN
to/TO
calculate/VB
the/DT
conformation/NN
of/IN
a/DT
receptor-ligand/JJ
complex/NN
./.
====================
It/PRP
is/VBZ
used/VBN
to/TO
identify/VB
the/DT
binding/NN
affinity/NN
and/CC
interaction/NN
energy/NN
of/IN
the/DT
molecules/NNS
with/IN
the/DT
target/NN
protein/NN
./.
====================
Docking/VBG
analysis/NN
was/VBD
performed/VBN
by/IN
AutoDock/NN
Vina/NN
[/(
24/CD
]/)
,/,
which/WDT
is/VBZ
an/DT
automated/JJ
procedure/NN
for/IN
predicting/VBG
the/DT
interaction/NN
of/IN
ligands/NNS
with/IN
bio-macromolecular/JJ
targets/NNS
./.
====================
Before/IN
initiating/VBG
the/DT
docking/NN
stimulations/NNS
,/,
phosphoglucosamine/NN
mutase/NN
protein/NN
was/VBD
modified/VBN
by/IN
adding/VBG
polar/JJ
hydrogen/NN
,/,
removing/VBG
all/DT
the/DT
water/NN
molecules/NNS
,/,
and/CC
was/VBD
also/RB
set/VBP
with/IN
the/DT
grid/JJ
box/NN
for/IN
its/PRP$
binding/VBG
site/NN
,/,
whereas/IN
all/DT
the/DT
torsional/JJ
bonds/NNS
of/IN
ligands/NNS
were/VBD
set/RB
free/JJ
by/IN
the/DT
ligand/NN
module/NN
./.
====================
To/TO
evaluate/VB
the/DT
binding/VBG
energy/NN
on/IN
the/DT
macromolecule/NN
coordinate/JJ
,/,
a/DT
three-dimensional/JJ
grid/JJ
box/NN
(/(
box/NN
size/NN
,/,
76/CD
×/NN
76/CD
×/NN
76/CD
Å/NNP
;/:
box/NN
center/NN
,/,
11/CD
×/NN
90.5/CD
×/CD
57.5/CD
for/IN
x/CC
,/,
y/RB
,/,
and/CC
z/NN
,/,
respectively/RB
)/)
was/VBD
created/VBN
using/VBG
Auto/JJ
Grid/JJ
,/,
which/WDT
calculates/VBZ
the/DT
grid/JJ
map/VBP
./.
====================
The/DT
combined/JJ
binding/NN
with/IN
target/NN
protein/NN
phosphoglucosamine/NN
mutase/NN
and/CC
ligand/NN
,/,
s-mercaptocysteine/NN
,/,
was/VBD
obtained/VBN
by/IN
using/VBG
PyMOL/NN
(/(
The/DT
PyMOL/NN
Molecular/JJ
Graphics/NNS
System/NN
,/,
version/NN
1.5.0.4/CD
,/,
Schrödinger/NNP
,/,
LLC/NN
)/)
[/(
25/CD
]/)
./.
====================
The/DT
UniProt/JJ
Knowledge/NN
Base/NN
(/(
UniProtKB/NN
)/)
delivers/VBZ
an/DT
authoritative/JJ
resource/NN
for/IN
protein/NN
sequences/NNS
and/CC
functional/JJ
information/NN
./.
====================
Sequences/NNS
of/IN
phosphoglucosamine/NN
mutase/NN
of/IN
Legionella/NN
pneumophilia/NN
(/(
strain/NN
Paris/NN
)/)
were/VBD
obtained/VBN
from/IN
UniProtKB/JJ
./.
====================
Manual/JJ
annotation/NN
is/VBZ
the/DT
landmark/NN
of/IN
the/DT
SwissProt/NN
section/NN
of/IN
UniProtKB/JJ
[/(
26/CD
,/,
27/CD
]/)
./.
====================
The/DT
protein/NN
sequence/NN
was/VBD
analyzed/VBN
using/VBG
the/DT
ProtParam/NN
server/RB
[/(
28/CD
]/)
,/,
which/WDT
can/MD
predict/VB
the/DT
physical/JJ
and/CC
chemical/JJ
parameters/NNS
for/IN
the/DT
protein/NN
./.
====================
The/DT
parameters/NNS
of/IN
this/DT
server/NN
are/VBP
helpful/JJ
for/IN
experimental/JJ
handling/NN
of/IN
the/DT
protein/NN
,/,
like/IN
biological/JJ
analysis/NN
or/CC
extraction/NN
./.
====================
ProtParam/NN
results/NNS
reveal/VBP
that/IN
the/DT
protein/NN
has/VBZ
23,295/CD
extinction/NN
coefficients/NNS
,/,
27.68/CD
instability/NN
index/NN
,/,
108.00/CD
aliphatic/JJ
index/NN
,/,
and/CC
0.059/CD
grand/CC
average/NN
of/IN
hydrophobicity/NN
,/,
with/IN
more/RBR
positively/RB
charged/VBN
residues/NNS
than/IN
negatively/RB
charged/VBN
amino/NN
acids/NNS
./.
====================
The/DT
physico-chemical/JJ
properties/NNS
of/IN
phosphoglucosamine/NN
mutase/NN
are/VBP
tabulated/VBN
in/IN
Table/JJ
1/CD
./.
====================
Secondary/JJ
structure/NN
analysis/NN
is/VBZ
increasing/VBG
day/NN
by/IN
day/NN
to/TO
predict/VB
protein/NN
function/NN
and/CC
structure/NN
./.
====================
The/DT
secondary/JJ
structure/NN
of/IN
phosphoglucosamine/NN
mutase/NN
was/VBD
predicted/VBN
by/IN
SOPMA/NN
with/IN
standard/JJ
parameters/NNS
./.
====================
Secondary/JJ
structure/NN
parameters/NNS
of/IN
phosphoglucosamine/NN
mutase/NN
are/VBP
presented/VBN
in/IN
a/DT
tabulated/JJ
form/VBP
in/IN
Table/JJ
2/CD
,/,
which/WDT
shows/VBZ
it/PRP
contains/VBZ
42.64/CD
%/NN
alpha/NN
helix/NN
,/,
18.80/CD
%/NN
extended/VBD
strand/NN
,/,
9.89/CD
%/NN
beta/NN
turn/NN
,/,
and/CC
29.69/CD
%/NN
random/JJ
coil/JJ
./.
====================
The/DT
graphical/JJ
secondary/JJ
structure/NN
of/IN
phosphoglucosamine/NN
mutase/NN
is/VBZ
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
PPI/NN
network/NN
generation/NN
has/VBZ
become/VBN
very/RB
important/JJ
tool/NN
of/IN
the/DT
modern/NN
biomedical/JJ
research/NN
arena/NNS
for/IN
the/DT
understanding/NN
of/IN
complex/NN
molecular/JJ
mechanisms/NNS
and/CC
the/DT
detection/NN
of/IN
novel/JJ
modulators/NNS
of/IN
disease/NN
processes/NNS
./.
====================
These/DT
types/NNS
of/IN
work/NN
have/VBP
been/VBN
shown/VBN
to/TO
be/VB
very/RB
important/JJ
in/IN
the/DT
study/NN
of/IN
a/DT
wide/JJ
range/NN
of/IN
human/JJ
diseases/NNS
,/,
as/IN
well/RB
as/IN
their/PRP$
signaling/NN
pathways/NNS
[/(
29/CD
,/,
30/CD
,/,
31/CD
]/)
./.
====================
PPI/NN
of/IN
phosphoglucosamine/NN
mutase/NN
was/VBD
generated/VBN
through/IN
STRING/NN
,/,
presented/VBN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
STRING/NN
forecasts/VBZ
a/DT
confidence/NN
score/RB
and/CC
3D/NN
structures/NNS
of/IN
protein/NN
and/CC
protein/NN
domains/NNS
./.
====================
Confidence/NN
scores/VBZ
were/VBD
generated/VBN
on/IN
the/DT
basis/NN
of/IN
different/JJ
parameters/NNS
,/,
like/IN
neighborhood/JJ
,/,
co-occurrence/NN
,/,
coexpression/NN
,/,
and/CC
homology/NN
./.
====================
STRING/NN
utilizes/VBZ
references/VBZ
from/IN
UniProt/JJ
and/CC
predicts/VBZ
functions/NNS
of/IN
different/JJ
interacting/VBG
proteins/NNS
./.
====================
PPI/NN
network/NN
demonstrates/VBZ
that/IN
phosphoglucosamine/NN
mutase/NN
interacts/VBZ
with/IN
10/CD
other/JJ
proteins/NNS
,/,
such/JJ
as/IN
mur/JJ
E/NN
is/VBZ
hypothetical/JJ
protein/NN
with/IN
a/DT
confidence/NN
score/RB
of/IN
0.687/CD
;/:
glmU/NN
is/VBZ
bifunctional/JJ
N-acetylglucosamine-1-phosphate/NN
(/(
Glc-N-1-P/NN
)/)
uridyltransferase/glucosamine-1-phosphate/VBP
N-acetyltransferase/NN
(/(
UDP-GlcNAc/NNP
)/)
,/,
which/WDT
catalyzes/VBZ
the/DT
last/JJ
two/CD
sequential/JJ
reactions/NNS
in/IN
the/DT
de/FW
novo/FW
biosynthetic/JJ
pathway/NN
for/IN
UDP-GlcNAc/JJ
./.
====================
It/PRP
is/VBZ
also/RB
responsible/JJ
for/IN
the/DT
acetylation/NN
of/IN
Glc-N-1-P/NN
to/TO
give/VB
GlcNAc-1-P/NN
and/CC
for/IN
the/DT
uridyl/JJ
transfer/NN
from/IN
UTP/NN
to/TO
GlcNAc-1-P/NN
,/,
which/WDT
produces/VBZ
UDP-GlcNAc/JJ
./.
====================
This/DT
protein/NN
is/VBZ
closely/RB
related/JJ
to/TO
glmM/NN
with/IN
the/DT
highest/JJS
confidence/NN
score/RB
(/(
0.998/CD
)/)
./.
====================
The/DT
second/JJ
highest/JJS
confidence/NN
protein/NN
is/VBZ
glmS/JJ
,/,
glucosamine-fructose-6-phosphate/NN
aminotransferase/NN
,/,
which/WDT
catalyzes/VBZ
the/DT
first/JJ
step/NN
in/IN
hexosamine/NN
metabolism/NN
,/,
converting/VBG
fructose-6P/NN
into/IN
glucosamine-6P/NN
using/VBG
glutamine/NN
as/IN
a/DT
nitrogen/NN
source/NN
./.
====================
Another/DT
important/JJ
protein/NN
,/,
murC/JJ
(/(
confidence/NN
score/RB
,/,
0.667/CD
)/)
,/,
UDP-N-acetylmuramate-L-alanine/NN
ligase/NN
,/,
works/VBZ
in/IN
cell/NN
wall/NN
formation/NN
./.
====================
Homology/NN
modeling/VBG
of/IN
the/DT
unique/JJ
and/CC
essential/JJ
metabolic/JJ
protein/NN
was/VBD
done/VBN
by/IN
using/VBG
Phyre2/NN
in/IN
order/NN
to/TO
obtain/VB
the/DT
3D/NN
structure/NN
of/IN
them/PRP
./.
====================
3D/RB
protein/NN
structures/NNS
give/VBP
important/JJ
insights/NNS
about/IN
the/DT
molecular/JJ
basis/NN
of/IN
protein/NN
function/NN
and/CC
thereby/RB
allow/VBP
an/DT
effective/JJ
design/NN
of/IN
experiments/NNS
[/(
32/CD
]/)
./.
====================
That/DT
is/VBZ
why/WRB
,/,
in/IN
the/DT
understanding/NN
and/CC
manipulation/NN
of/IN
biochemical/JJ
and/CC
cellular/JJ
functions/NNS
of/IN
proteins/NNS
,/,
the/DT
high-resolution/JJ
3D/NN
structure/NN
of/IN
a/DT
protein/NN
is/VBZ
the/DT
main/JJ
key/JJ
[/(
19/CD
]/)
./.
====================
Phyre2/NN
generated/VBN
the/DT
best/JJS
suited/VBN
result/NN
,/,
showing/VBG
that/IN
the/DT
predicted/VBN
structure/NN
had/VBD
a/DT
100/CD
%/NN
confidence/NN
level/NN
and/CC
uses/VBZ
the/DT
template/NN
c3pdkB/NN
./.
====================
Secondary/JJ
structure/NN
and/CC
disorder/NN
prediction/NN
leads/VBZ
to/TO
a/DT
conclusion/NN
that/IN
phosphoglucosamine/NN
mutase/NN
has/VBZ
disordered/VBN
region/NN
of/IN
4/CD
%/NN
./.
====================
To/TO
gain/VB
a/DT
more/RBR
accurate/JJ
model/NN
,/,
refinement/JJ
through/IN
ModRefiner/NN
was/VBD
done/VBN
./.
====================
After/IN
derivation/NN
by/IN
the/DT
ModRefiner/NN
,/,
the/DT
refined/VBN
model/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
of/IN
the/DT
desired/VBN
enzyme/NN
was/VBD
analyzed/VBN
for/IN
further/JJ
advancement/JJ
./.
====================
In/IN
the/DT
initial/JJ
model/NN
of/IN
phosphoglucosamine/NN
mutase/NN
,/,
the/DT
percent/JJ
of/IN
residues/NNS
in/IN
the/DT
favored/JJ
region/NN
in/IN
the/DT
Ramachandran/NN
plot/NN
was/VBD
84.0/CD
%/NN
versus/CC
95.0/CD
%/NN
in/IN
the/DT
final/JJ
model/NN
./.
====================
The/DT
red/JJ
,/,
brown/VBN
,/,
and/CC
yellow/IN
colored/JJ
regions/NNS
are/VBP
the/DT
symbol/NN
of/IN
the/DT
favored/JJ
,/,
allowed/VBD
,/,
and/CC
generously/RB
allowed/VBD
regions/NNS
,/,
respectively/RB
,/,
the/DT
same/JJ
as/IN
defined/VBN
by/IN
PROCHECK/NN
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
Parameters/NNS
,/,
such/JJ
as/IN
residue/NN
in/IN
the/DT
favored/JJ
,/,
allowed/VBD
,/,
and/CC
generously/RB
allowed/VBD
region/NN
and/CC
G-factor/NN
,/,
are/VBP
the/DT
determinants/NNS
of/IN
a/DT
good/JJ
model/NN
[/(
33/CD
,/,
34/CD
,/,
35/CD
]/)
./.
====================
Subsequent/JJ
to/TO
that/DT
,/,
PROCHECK/NN
was/VBD
used/VBN
to/TO
measure/VB
the/DT
accuracy/NN
of/IN
protein/NN
models/NNS
./.
====================
Parameter/NN
comparisons/NNS
of/IN
these/DT
proteins/NNS
were/VBD
made/VBN
with/IN
well-refined/JJ
structures/NNS
that/DT
have/VBP
similar/JJ
resolution/NN
./.
====================
Through/IN
PROCHECK/NN
analysis/NN
,/,
specific/JJ
information/NN
about/IN
the/DT
protein/NN
chains/NNS
and/CC
their/PRP$
stereochemical/JJ
quality/NN
,/,
like/IN
Ramachandran/NN
plot/NN
quality/NN
,/,
peptide/NN
bond/NN
planarity/NN
,/,
bad/NN
non-bonded/JJ
interactions/NNS
,/,
main/JJ
chain/NN
hydrogen/NN
bond/NN
energy/NN
,/,
C/NN
alpha/NN
chirality/NN
,/,
and/CC
overall/JJ
G/NN
factor/NN
,/,
and/CC
the/DT
side/JJ
chain/NN
parameters/NNS
like/IN
standard/JJ
deviations/NNS
of/IN
chi1/NN
gauche/DT
minus/JJ
,/,
can/MD
be/VB
obtained/VBN
[/(
36/CD
]/)
./.
====================
Ramachandran/NN
plot/NN
statistics/NNS
of/IN
phosphoglucosamine/NN
mutase/NN
revealed/VBD
that/IN
most/JJS
of/IN
the/DT
amino/NN
acid/NN
residues/NNS
(/(
above/JJ
90/CD
%/NN
of/IN
amino/NN
acid/NN
residues/NNS
)/)
were/VBD
present/JJ
in/IN
most/JJS
favored/VBD
regions/NNS
(/(
Table/JJ
3/CD
)/)
./.
====================
Thus/RB
,/,
the/DT
protein/NN
model/NN
was/VBD
very/RB
good/JJ
,/,
seeing/VBG
that/DT
all/DT
of/IN
the/DT
residues/NNS
were/VBD
within/IN
the/DT
limits/NNS
of/IN
the/DT
Ramachandran/NN
plot/NN
./.
====================
Verification/NN
was/VBD
also/RB
done/VBN
by/IN
ERRAT/NN
,/,
Verify3D/NNP
,/,
and/CC
QMEAN/NN
server/RB
./.
====================
ERRAT/NN
uses/VBZ
a/DT
quadratic/JJ
error/NN
function/NN
to/TO
characterize/VB
and/CC
differentiate/VBP
between/IN
correctly/RB
and/CC
incorrectly/RB
determined/VBN
regions/NNS
of/IN
protein/NN
structures/NNS
based/VBN
on/IN
characteristic/JJ
atomic/JJ
interaction/NN
[/(
37/CD
]/)
./.
====================
The/DT
overall/JJ
quality/NN
of/IN
the/DT
model/NN
by/IN
ERRAT/NN
analysis/NN
was/VBD
89.791/CD
./.
====================
The/DT
Verify3D/JJ
graph/NN
value/NN
of/IN
the/DT
model/NN
is/VBZ
0.71/CD
,/,
which/WDT
indicates/VBZ
that/IN
the/DT
environmental/JJ
profile/NN
of/IN
phosphoglucosamine/NN
mutase/NN
is/VBZ
quite/RB
good/JJ
[/(
38/CD
,/,
39/CD
,/,
40/CD
]/)
./.
====================
On/IN
the/DT
basis/NN
of/IN
a/DT
linear/JJ
combination/NN
of/IN
six/CD
structural/JJ
descriptions/NNS
,/,
the/DT
QMEAN/NN
scoring/VBG
function/NN
estimates/NNS
the/DT
global/JJ
quality/NN
of/IN
the/DT
models/NNS
./.
====================
The/DT
local/JJ
geometry/NN
model/NN
analysis/NN
is/VBZ
done/VBN
by/IN
a/DT
torsion/NN
angel/NN
potential/JJ
over/IN
three/CD
consecutive/JJ
amino/NN
acids/NNS
,/,
and/CC
the/DT
quality/NN
of/IN
the/DT
model/NN
can/MD
be/VB
compared/VBN
to/TO
a/DT
reference/NN
structure/NN
of/IN
high/JJ
resolution/NN
obtained/VBN
from/IN
X-ray/NN
crystallography/NN
analysis/NN
through/IN
Z/NN
score/RB
./.
====================
QMEAN/NN
Z-score/RB
provides/VBZ
an/DT
estimation/NN
of/IN
the/DT
``/NN
degree/NN
of/IN
nativeness/JJ
''/CD
of/IN
the/DT
structural/JJ
features/NNS
observed/VBN
in/IN
a/DT
model/NN
and/CC
indicates/VBZ
that/IN
the/DT
model/NN
is/VBZ
of/IN
comparable/JJ
quality/NN
to/TO
experimental/JJ
structures/NNS
[/(
41/CD
]/)
./.
====================
The/DT
assessing/VBG
of/IN
long-range/JJ
interactions/NNS
is/VBZ
carried/VBN
through/IN
secondary/JJ
structure/NN
specific/JJ
distance-dependent/JJ
pairwise/JJ
residue/NN
level/NN
potential/JJ
./.
====================
A/DT
solvation/JJ
potential/JJ
describes/VBZ
the/DT
burial/JJ
status/NN
of/IN
the/DT
residues/NNS
./.
====================
Secondary/JJ
structure/NN
element/NN
and/CC
accessibility/NN
agreement/NN
ensures/VBZ
the/DT
quality/NN
assessment/NN
between/IN
the/DT
predicted/VBN
and/CC
calculated/VBN
secondary/JJ
structure/NN
and/CC
solvent/JJ
accessibility/NN
[/(
21/CD
]/)
./.
====================
The/DT
respective/JJ
values/NNS
of/IN
Z-scores/NNS
of/IN
C_β/JJ
interaction/NN
energy/NN
,/,
solvation/JJ
energy/NN
,/,
torsion/NN
angle/JJ
energy/NN
,/,
secondary/JJ
structure/NN
,/,
and/CC
solvent/JJ
accessibility/NN
are/VBP
0.28/CD
,/,
-1.03/CD
,/,
-1.20/CD
,/,
1.43/CD
,/,
and/CC
1.12/CD
in/IN
the/DT
case/NN
of/IN
phosphoglucosamine/NN
mutase/NN
,/,
as/IN
shown/VBN
in/IN
Table/JJ
4/CD
./.
====================
The/DT
overall/JJ
QMEAN/NN
score/NN
for/IN
phosphoglucosamine/NN
mutase/NN
is/VBZ
1.11/CD
./.
====================
QMEAN-generated/JJ
results/NNS
confer/VBP
phosphoglucosamine/NN
mutase/NN
as/IN
a/DT
qualified/VBN
model/NN
for/IN
further/JJ
drug/NN
target/NN
scopes/NNS
./.
====================
The/DT
active/JJ
site/NN
of/IN
phosphoglucosamine/NN
mutase/NN
was/VBD
predicted/VBN
by/IN
using/VBG
CASTp/NN
server/RB
./.
====================
Further/RB
,/,
in/IN
this/DT
study/NN
,/,
we/PRP
have/VBP
also/RB
reported/VBD
the/DT
best/JJS
active/JJ
site/NN
area/NN
of/IN
the/DT
experimental/JJ
enzyme/NN
,/,
as/IN
well/RB
as/IN
the/DT
number/NN
of/IN
amino/NN
acids/NNS
involved/VBN
in/IN
it/PRP
./.
====================
Fig/NN
./.
====================
5/CD
shows/VBZ
the/DT
interacting/VBG
residues/NNS
Arg419/NN
,/,
Thr414/NN
,/,
Ser412/NN
,/,
and/CC
Thr9/NN
with/IN
protein-ligand/CC
from/IN
the/DT
docking/NN
that/DT
had/VBD
been/VBN
suggested/VBN
by/IN
CASTp/NN
which/WDT
was/VBD
found/VBN
in/IN
the/DT
active/JJ
site/NN
of/IN
phosphoglucosamine/NN
mutase/NN
./.
====================
In/IN
order/NN
to/TO
understand/VB
docking/NN
studies/NNS
with/IN
phosphoglucosamine/NN
mutase/NN
and/CC
s-mercaptocysteine/NN
,/,
analysis/NN
of/IN
lowest/JJ
docked/VBD
energy/NN
value/NN
,/,
calculated/VBN
Root/NN
mean/JJ
square/VBP
deviation/NN
value/NN
,/,
involvement/NN
of/IN
H/NN
bonds/NNS
,/,
and/CC
interacting/VBG
residues/NNS
was/VBD
considered/VBN
(/(
Table/JJ
5/CD
)/)
./.
====================
Least/NN
docked/VBD
energy/NN
postulates/VBZ
a/DT
better/RBR
docking/NN
result/NN
./.
====================
Receptor-ligand/CC
analysis/NN
of/IN
our/PRP$
predicted/VBN
protein/NN
shows/VBZ
the/DT
lowest/JJS
energy/NN
of/IN
-4.0/CD
kcal/mol/NN
,/,
as/IN
well/RB
as/IN
a/DT
root/NN
mean/JJ
square/VBP
distance/NN
of/IN
0.000/CD
Å/NN
,/,
and/CC
it/PRP
contains/VBZ
four/CD
hydrogen/NN
bonds/NNS
./.
====================
Thr414/NN
,/,
Val306/NN
,/,
Asp308/NN
,/,
Gly307/NN
,/,
Thr9/NN
,/,
Asp10/NN
,/,
and/CC
Ser412/NN
are/VBP
the/DT
interacting/VBG
molecules/NNS
where/WRB
ligand/NN
interacts/VBZ
with/IN
the/DT
protein/NN
receptor/NN
./.
====================
S-mercaptocysteine/NN
(/(
3-disulfanyl-L-alanine/NN
(/(
2R/NN
)/)
-2-amino-3-disulfanyl-propanoic/JJ
acid/NN
)/)
,/,
which/WDT
has/VBZ
a/DT
molecular/JJ
weight/NN
of/IN
153.22/CD
g/mol/NN
(/(
Table/JJ
6/CD
)/)
,/,
was/VBD
found/VBN
to/TO
bind/VB
at/IN
the/DT
active/JJ
site/NN
of/IN
phosphoglucosamine/NN
mutase/NN
with/IN
the/DT
lowest/JJS
binding/VBG
energy/NN
(/(
Fig/NN
./.
====================
6/CD
)/)
./.
====================
It/PRP
has/VBZ
been/VBN
clear/JJ
that/IN
s-mercaptocysteine/VBP
formed/VBD
similar/JJ
hydrogen/NN
bond/NN
interactions/NNS
with/IN
phosphoglucosamine/NN
mutase/NN
./.
====================
From/IN
the/DT
active/JJ
site/NN
analysis/NN
,/,
41/CD
amino/NN
acid/NN
residues/NNS
were/VBD
found/VBN
in/IN
the/DT
potent/JJ
active/JJ
site/NN
./.
====================
The/DT
interaction/NN
between/IN
the/DT
active/JJ
site/NN
residues/NNS
and/CC
the/DT
ligand/NN
found/VBN
in/IN
our/PRP$
present/JJ
study/NN
is/VBZ
useful/JJ
for/IN
perceiving/VBG
the/DT
potential/JJ
mechanism/NN
of/IN
residues/NNS
and/CC
the/DT
drug/NN
binding/NN
./.
====================
The/DT
hydrogen/NN
bonds/NNS
play/VBP
a/DT
significant/JJ
role/NN
for/IN
the/DT
structure/NN
and/CC
function/NN
of/IN
biological/JJ
molecules/NNS
,/,
and/CC
we/PRP
found/VBD
significant/JJ
results/NNS
./.
====================
Among/IN
the/DT
41/CD
residues/NNS
,/,
Thr9/NN
,/,
Arg246/NN
,/,
Val306/NN
,/,
Gly307/NN
,/,
Asp308/NN
,/,
Ser412/NN
,/,
and/CC
Thr414/NN
interacted/VBD
with/IN
the/DT
ligand/NN
;/:
the/DT
others/NNS
did/VBD
not/RB
./.
====================
Docking/VBG
analysis/NN
with/IN
ligand/NN
identified/VBN
specific/JJ
residues-viz/NN
./.
====================
Thr414/NN
,/,
Ser412/NN
,/,
and/CC
Thr9/NN
(/(
Fig/NN
./.
====================
7/CD
)/)
-within/NN
the/DT
phosphoglucosamine/NN
mutase/NN
binding/VBG
pocket/NN
to/TO
play/VB
an/DT
important/JJ
role/NN
in/IN
ligand/NN
binding/NN
affinity/NN
,/,
which/WDT
further/RB
itself/PRP
inhibits/VBZ
its/PRP$
function/NN
and/CC
exposes/VBZ
studies/NNS
about/IN
new/JJ
drug/NN
discovery/NN
./.
====================
The/DT
putative/JJ
drug/NN
targets/NNS
phosphoglucosamine/NN
mutase/NN
,/,
phosphoglyceromutase/NN
,/,
and/CC
phosphomannomutase/NN
for/IN
legionellosis/NN
have/VBP
been/VBN
reported/VBN
as/IN
potential/JJ
in/IN
the/DT
literature/NN
./.
====================
That/DT
is/VBZ
why/WRB
in/IN
our/PRP$
study/NN
,/,
the/DT
3D/NN
structure/NN
of/IN
phosphoglucosamine/NN
mutase/NN
from/IN
L./FW
pneumophila/FW
(/(
strain/NN
Paris/NN
)/)
was/VBD
predicted/VBN
and/CC
validated/VBD
by/IN
a/DT
variety/NN
of/IN
bioinformatics/NNS
tools/NNS
and/CC
software/JJ
./.
====================
Analyzing/VBG
the/DT
results/NNS
,/,
it/PRP
could/MD
be/VB
concluded/VBN
that/IN
future/JJ
characterization/NN
of/IN
phosphoglucosamine/NN
mutase/NN
from/IN
L./FW
pneumophila/FW
(/(
strain/NN
Paris/NN
)/)
will/MD
be/VB
noteworthy/RB
for/IN
the/DT
regulation/NN
of/IN
legionellosis/NN
./.
====================
The/DT
modeled/JJ
3D/NN
structure/NN
will/MD
provide/VB
a/DT
good-quality/NN
foundation/NN
for/IN
experimental/JJ
development/NN
of/IN
the/DT
crystal/JJ
structure/NN
,/,
and/CC
the/DT
molecular/JJ
docking/NN
study/NN
will/MD
assist/VB
efficient/JJ
inhibitor/NN
design/NN
against/IN
legionellosis/NN
in/IN
the/DT
future/JJ
./.
====================
Predicted/VBN
secondary/JJ
structure/NN
of/IN
phosphoglucosamine/NN
mutase/NN
./.
====================
Here/RB
,/,
helix/NN
is/VBZ
indicated/VBN
by/IN
blue/JJ
,/,
while/IN
extended/VBD
strands/NNS
and/CC
beta/NN
turns/NNS
are/VBP
indicated/VBN
by/IN
red/JJ
and/CC
green/VBN
,/,
respectively/RB
./.
====================
Protein-protein/NN
interaction/NN
network/NN
of/IN
phosphoglucosamine/NN
mutase/NN
./.
====================
Refined/VBN
model/NN
of/IN
the/DT
protein/NN
phosphoglucosamine/NN
mutase/NN
./.
====================
Ramachandran/NN
plot/NN
analysis/NN
of/IN
predicted/VBN
protein/NN
through/IN
Swiss/JJ
model/NN
Workshop/NNP
./.
====================
Active/JJ
site/NN
determination/NN
of/IN
the/DT
phosphoglucosamine/NN
mutase/NN
protein/NN
./.
====================
(/(
A/NN
)/)
The/DT
green/VBN
region/NN
indicates/VBZ
the/DT
most/JJS
potent/JJ
active/JJ
site/NN
./.
====================
(/(
B/NN
)/)
The/DT
amino/NN
acid/NN
residues/NNS
in/IN
the/DT
active/JJ
site/NN
./.
====================
The/DT
overall/JJ
binding/NN
between/IN
the/DT
phosphoglucosamine/NN
mutase/NN
and/CC
S-mercaptocysteine/NN
./.
====================
Graphical/JJ
representation/NN
of/IN
docking/NN
study/NN
between/IN
S-mercaptocysteine/NN
and/CC
phosphoglucosamine/NN
mutase/NN
(/(
yellow/RB
dashed/VBN
lines/NNS
indicate/VBP
hydrogen/NN
bonds/NNS
)/)
./.
====================
(/(
A/NN
)/)
Visualization/NN
of/IN
S-mercaptocysteine-phosphoglucosamine/NN
mutase/NN
./.
====================
(/(
B/NN
)/)
Hydrogen/NN
bond/NN
detection/NN
through/IN
PyMOL/NN
./.
====================
Physicochemical/JJ
properties/NNS
of/IN
phosphoglucosamine/NN
mutase/NN
from/IN
Legionella/NN
pneumophila/NN
(/(
strain/NN
Paris/NN
)/)
====================
Calculated/JJ
secondary/JJ
structure/NN
elements/NNS
of/IN
phosphoglucosamine/NN
mutase/NN
of/IN
Legionella/NN
pneumophila/NN
by/IN
SOPMA/NN
====================
Ramachandran/NN
plot/NN
statistics/NNS
of/IN
phosphoglucosamine/NN
mutase/NN
from/IN
Legionella/NN
pneumophila/NN
(/(
strain/NN
Paris/NN
)/)
====================
Z-scores/NNS
of/IN
QMEAN/NN
for/IN
individual/JJ
component/NN
====================
Comparative/JJ
docking/NN
study/NN
of/IN
the/DT
ligand/NN
to/TO
the/DT
target/NN
====================
Description/NN
of/IN
the/DT
ligand/NN
molecule/NN
====================
